Optic Nerve Tumor in Tuberous Sclerosis Complex is not Responsive to Sirolimus

Pediatric Neurology

Volumn 42, Issue 6, 2010, Pages 443-446

  Sparagana, Steven P ^a,b   Wilkes, David C ^a   Thompson, Catherine E ^a   Bowers, Daniel C ^b  

^a TEXAS SCOTTISH RITE HOSPITAL FOR CHILDREN   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETIRACETAM; RAPAMYCIN; VIGABATRIN;

ARTICLE; BRAIN VENTRICLE PERITONEUM SHUNT; CASE REPORT; CHILD; COMPLEX PARTIAL SEIZURE; CONTRAST ENHANCEMENT; DRUG RESPONSE; FAMILY HISTORY; FEMALE; GIANT CELL TUMOR; HUMAN; HYDROCEPHALUS; LOW DRUG DOSE; NEUROSURGERY; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC NERVE TUMOR; PRIORITY JOURNAL; SCHOOL CHILD; SUBEPENDYMOMA; TREATMENT DURATION; TUBEROUS SCLEROSIS; TUMOR GROWTH; TUMOR VOLUME; VISUAL ACUITY;

ANTIBIOTICS, ANTINEOPLASTIC; ASTROCYTOMA; BRAIN NEOPLASMS; CHILD; FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL; OPTIC NERVE NEOPLASMS; SIROLIMUS; TREATMENT OUTCOME; TUBEROUS SCLEROSIS;

EID: 77952107081     PISSN: 08878994     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pediatrneurol.2010.01.016     Document Type: Article

References (9)

1. Robertson D.M. Ophthalmic findings. In: Gomez M.R., Sampson J.R., and Whittemore V.H. (Eds). Tuberous sclerosis complex. 3rd ed (1999), Oxford University Press, New York 145-159
2. Erbay S.H., Oljeski S.A., and Bhadelia R. Rapid development of optic glioma in a patient with hybrid phakomatosis: Neurofibromatosis type 1 and tuberous sclerosis. AJNR 25 (2004) 36-38
3. Franz D.N., Leonard J., Tudor C., et al. Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Ann Neurol 59 (2006) 490-498
4. Koenig M.K., Butler I.J., and Northrup H. Regression of subependymal giant cell astrocytoma with rapamycin in tuberous sclerosis complex. J Child Neurol 23 (2008) 1238-1239
5. Wienecke R., Fackler I., Linsenmaier U., Mayer K., Licht T., and Kretzler M. Antitumoral activity of rapamycin in renal angiomyolipoma associated with tuberous sclerosis complex. Am J Kidney Dis 48 (2006) e27-e29
6. Hofbauer G.F., Marcollo-Pini A., Corsenca A., et al. The mTOR inhibitor rapamycin significantly improves facial angiofibroma lesions in a patient with tuberous sclerosis. Br J Dermatol 159 (2008) 473-475
7. Bissler J.J., McCormack F.X., Young L.R., et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med 358 (2008) 140-151
8. Listernick R., Frener R., Liu G., and Gutmann D. Optic pathway gliomas in neurofibromatosis-1: Controversies and recommendations. Ann Neurol 61 (2007) 189-198
9. Lee N., Woodrum C., Nobil A., Rauktys A., Messina M., and Dabora S. Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical models. BMC Pharm 9 (2009) 1-15